The 1st China Pharmaceutical Innovation Conference (CPIC), hosted by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).

Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of "Chinese Innovation – Global Translation – Shanghai Transaction." As the "premier window" for global capital and enterprises to gain insight into China's innovation ecosystem, and as the "core hub" for Chinese pharmaceutical companies to upgrade, go global, and connect with the world, CPIC is set to become the definitive barometer for annual investment and collaboration in the global health industry. The conference will feature dozens of dedicated sessions covering numerous hot topics and future directions in health industry innovation investment and globalization.

With the rapid development of emerging market economies and the growing demand for innovative drugs, coupled with continuous improvements in technology transfer, drug access, and reimbursement systems across various countries, Chinese pharmaceutical companies stand at a critical turning point in their globalization journey. To address this, Legend Capital, Rxilient, and TONACEA are jointly hosting a special session themed "Global Development of Pharmaceutical Enterprises and Emerging Market Collaboration." The session will focus on the latest policies, market opportunities and challenges, product and industry go-to-market strategies, and localization practices in Southeast Asia, the Middle East and North Africa, and Latin America. The session aims to provide participants with a practical and efficient platform for dialogue, fostering extensive exchanges and in-depth collaboration, and jointly exploring sustainable, high-quality paths to global expansion.

Session Theme | Global Development of Pharmaceutical Enterprises and Emerging Market Collaboration
Organizers | Legend Capital, Rxilient, TONACEA
Date | July 23, 2026, 09:00–17:30
Venue | Hall 4.2, National Exhibition and Convention Center (Shanghai)

Detailed agenda is being developed. Stay tuned.

About Legend Capital

Founded in April 2001, Legend Capital is a leading professional investment firm in China focused on early-stage venture capital and growth-stage private equity investments.

Over more than two decades of development, Legend Capital has adhered to international standards, completed full fund cycles across multiple funds, and generated excellent and sustainable fund performance. To date, the firm has invested in over 600 companies, of which 121 have gone public on various global capital markets and nearly 100 have exited through mergers and acquisitions. Its portfolio includes industry-leading companies such as Cinda Bio, Ribobio, Yilian Bio, WuXi AppTec, Kanglonghua, iFlytek, and CATL, as well as numerous national-level "Little Giant" specialized and sophisticated enterprises and manufacturing champions. This has enabled Legend Capital to build a rich ecosystem of industrial resources.

About Rxilient

Rxilient was founded in October 2021 as a joint venture between China Medical System (CMS) and Legend Capital, with its headquarters in Singapore. The company focuses on global emerging markets, covering Southeast Asia, the Middle East and North Africa, Eastern Europe, and Latin America, while also expanding into mature markets such as Hong Kong, Macau, Taiwan, Australia, and New Zealand. As a next-generation pharma company centered on global emerging markets, Rxilient adheres to a "glocalization" strategy, committed to bringing innovation to emerging markets and building end-to-end local commercialization capabilities—from product sourcing from China and around the world to development, registration, manufacturing, and sales. Currently, the company has multiple products in the registration phase and several drugs successfully launched on the market, including ruxolitinib cream, the first drug approved by the U.S. FDA and the European EMA for the treatment of non-segmental vitiligo.

About TONACEA

TONACEA is a premier ecosystem platform in China's biomedical innovation sector. With over 20 years of deep engagement in China's innovative drug development, it has grown into a key organizational force driving China's pharmaceutical innovation and serves as a core hub connecting multinational pharmaceutical companies with local innovation.

TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing system that covers the entire R&D value chain. Its business encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With multiple branches across China, TONACEA has built an operational network that extends nationwide. Its official WeChat account and video channel consistently deliver in-depth industry insights, with perspectives frequently cited by investors and media, earning recognition as a trusted authoritative source within the industry.